Get the Stockscreener App
1.33
1.48%
-0.02
Precigen Inc stock is traded at $1.33, with a volume of 856.85K.
It is down -1.48% in the last 24 hours and down -4.32% over the past month.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
See More
Previous Close:
$1.35
Open:
$1.35
24h Volume:
856.85K
Relative Volume:
0.52
Market Cap:
$463.41M
Revenue:
$6.23M
Net Income/Loss:
$-95.90M
P/E Ratio:
-3.4103
EPS:
-0.39
Net Cash Flow:
$-68.47M
1W Performance:
-15.29%
1M Performance:
-4.32%
6M Performance:
+36.30%
1Y Performance:
+3.10%
1-Day Range:
$1.33
$1.42
1-Week Range:
$1.225
$1.595
52-Week Range:
$0.6513
$2.17
Precigen Inc Stock (PGEN) Company Profile
Name
Precigen Inc
Sector
Industry
Phone
301-556-9900
Address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Compare PGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
1.33 | 463.41M | 6.23M | -95.90M | -68.47M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-22-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-23-23 | Initiated | JP Morgan | Neutral |
| Nov-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-21 | Initiated | Stifel | Buy |
| Feb-22-21 | Initiated | Wells Fargo | Overweight |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| May-08-20 | Initiated | H.C. Wainwright | Buy |
View All
Precigen Inc Stock (PGEN) Latest News
Precigen : to Announce First Quarter 2020 Financial Results on May 6th - marketscreener.com
Precigen Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
LPL Financial LLC Trims Stock Position in Precigen, Inc. (NASDAQ:PGEN) - Defense World
There is no way Precigen Inc (PGEN) can keep these numbers up - Sete News
Precigen, Inc. (NASDAQ:PGEN) Shares Sold by Renaissance Technologies LLC - Defense World
Precigen Inc [PGEN] Insider Activity: An Update for Investors - knoxdaily.com
Precigen Inc (PGEN) stock analysis: A comprehensive overview - uspostnews.com
Geode Capital Management LLC Acquires 53,343 Shares of Precigen, Inc. (NASDAQ:PGEN) - Defense World
JPMorgan Chase & Co. Lowers Stock Position in Precigen, Inc. (NASDAQ:PGEN) - Defense World
Intrexon : Precigen Completes Series Of Transactions To Solidify Healthcare Focus - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
JP Morgan Downgrades Precigen Inc (PGEN) to an Underweight from a Neutral - knoxdaily.com
Franklin Resources Inc. Has $37,000 Stake in Precigen, Inc. (NASDAQ:PGEN) - Defense World
Precigen : to Participate in Upcoming JMP Securities Hematology and Oncology Forum - marketscreener.com
Major Rare Disease Summit: Precigen Tackles RRP Crisis Affecting 125,000 Patients - Stock Titan
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Precigen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - Business Wire
Exploring US High Growth Tech Stocks This April 2025 - simplywall.st
Precigen, Inc.'s (NASDAQ:PGEN) Profit Outlook - Yahoo Finance
Charles Schwab Investment Management Inc. Raises Stock Position in Precigen, Inc. (NASDAQ:PGEN) - Defense World
Is Precigen (PGEN) The Hot Biotech Stock Under $5? - Insider Monkey
Precigen, Inc. (NASDAQ:PGEN) Q4 2024 Earnings Call Transcript - Insider Monkey
Cantor Fitzgerald raises Precigen stock target to $5 By Investing.com - Investing.com Australia
Analysts Offer Predictions for Precigen FY2027 Earnings - Defense World
10 Hot Biotech Stocks Under $5 - Insider Monkey
Precigen’s Earnings Call: Positive Outlook Amid Challenges - TipRanks
Precigen Inc (PGEN) Q4 2024 Earnings Report Preview: What To Exp - GuruFocus
Precigen’s SWOT analysis: biotech firm’s stock poised for potential launch By Investing.com - Investing.com South Africa
Analysts Are Bullish on Precigen Stock (PGEN) Amid Positive Pipeline Developments - markets.businessinsider.com
ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Precigen, Inc. f/k/a Intrexon Corporation Investors of Important Deadline in Securities Class Action First Filed by the Firm – PGEN, XON - Business Wire
Stifel maintains Precigen stock Buy rating with $7 target By Investing.com - Investing.com South Africa
Precigen’s SWOT analysis: biotech firm’s stock poised for potential launch - Investing.com India
Expert Outlook: Precigen Through The Eyes Of 4 Analysts - Benzinga
Cantor Fitzgerald raises Precigen stock target to $5 - Investing.com
Stifel maintains Precigen stock Buy rating with $7 target - Investing.com
H.C. Wainwright reiterates buy on Precigen stock, maintains $6 target By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates buy on Precigen stock, maintains $6 target - Investing.com
Earnings call transcript: Precigen Q4 2024 sees net loss, stock rises By Investing.com - Investing.com South Africa
Precigen Inc (PGEN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Seizing ... - Yahoo Finance
Precigen Inc (PGEN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Seizing Opportunities - GuruFocus
Precigen earnings beat by $0.02, revenue fell short of estimates - Investing.com Canada
Precigen Reports Progress and Financial Results for 2024 - TipRanks
Precigen Reports Full Year 2024 Financial Results and Business Updates - The Malaysian Reserve
Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates - MSN
Earnings call transcript: Precigen Q4 2024 sees net loss, stock rises - Investing.com Canada
Precigen Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Precigen Inc Reports Q4 Net Loss of $(0.47) Per Share, Revenue o - GuruFocus.com
PRECIGEN, INC. SEC 10-K Report - TradingView
How Do Things Look For Precigen Inc (NASDAQ: PGEN) In The Short-Term? - Stocks Register
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Precigen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - Business Wire
Precigen, Inc. (NASDAQ:PGEN) Receives $7.00 Consensus Price Target from Brokerages - Defense World
Precigen Inc Stock (PGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):